<DOC>
	<DOC>NCT02229396</DOC>
	<brief_summary>Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with 24-week and 52-week extension phases of simultaneous administration of exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg once daily (QD) compared to EQW 2 mg alone and dapagliflozin 10 mg QD alone in patients with Type 2 diabetes who have inadequate glycemic control on metformin.</brief_summary>
	<brief_title>Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Inclusion criteria Has a diagnosis of T2DM. Has HbA1c of 8.0% to 12.0%, inclusive, at Visit 1 and Visit 2. Treated with a stable dose of metformin ≥1500 mg/day for at least 2 months prior to Screening. Exclusion criteria FPG ≥280 mg/dL (15.6 mmol/L). Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening) Clinically significant abnormal free T4 values or patients needing initiation or adjustment of thyroid treatment according to the investigator. Abnormal thyroid stimulating hormone (TSH) value at Screening will be further evaluated by free T4.Patients with clinically significant abnormal free T4 values will be excluded. Known active proliferative retinopathy. History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1 History or presence of inflammatory bowel disease or other severe GI diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis. History of gastric bypass surgery or gastric banding surgery, or either procedure is planned during the time period of the study. Current use of gastric balloons is also excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Diabetes medication</keyword>
	<keyword>Treatment efficacy</keyword>
	<keyword>Placebo</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Cardiovascular metabolic</keyword>
</DOC>